Spotlight On: What to Watch at AHA 2025 – Key Science and Trends

AHA 2025 Scientific Sessions take place from November 7–10, 2025, in New Orleans, LA, featuring 27 late-breaking science presentations across seven main sessions1 9.

One high-profile presentation is a first-in-human phase I clinical trial using CRISPR-Cas9 gene-editing therapy targeting ANGPTL3 for lipid metabolism disorders1.

The POLY-HF trial will detail the impact of a polypill strategy in heart failure patients, aiming at simplified and comprehensive pharmacologic therapy1.

Final results of the RECOVERY trial (early surgery vs conservative management in asymptomatic severe aortic stenosis) and the FAVOR IV-QVAS trial (FFR-guided CABG in valve disease) will be highlighted in late-breaking sessions1.

The CORALreef Lipids study will present data on an oral PCSK9 inhibitor (enlicitide decanoate), representing a potential paradigm shift in lipid management1.

Focus areas include cardiometabolic and lifestyle interventions after atrial fibrillation (AF), blood pressure control strategies, and advances in coronary artery disease management, including vitamin D and revascularization trials3 5.

A notable study (DECAF) will report on coffee consumption’s effect on recurrence of atrial fibrillation or flutter, with findings suggesting caffeinated coffee is linked to lower recurrence rates compared to abstinence5.

The CELEBRATE trial will highlight results on zalunfiban, showing reduced composite endpoints at 30 days in STEMI patients without increased severe bleeding, supporting new antiplatelet approaches5.

The session roster includes new recommendations for CPR and emergency heart care, such as a universal 'Chain of Survival,' updated choking relief protocols (alternating back blows and abdominal thrusts for adults, back blows and chest pushes for infants), opioid emergency guidelines (naloxone use), and cooling therapy for cardiac arrest survivors4 6.

Industry and regulatory updates address innovation in care delivery, equity, and cost reduction in cardiovascular disease management, aligning with the AHA’s ongoing 2025 advocacy priorities2 7.